J&J’s iBOT Wins Expedited FDA Approval, Faces Reimbursement Roadblocks
This article was originally published in The Gray Sheet
Executive Summary
FDA will evaluate the need for labeling revisions to Johnson & Johnson/Independence Technology's iBOT 3000 stair-climbing wheelchair upon receipt of four semi-annual reports from the company
You may also be interested in...
Medicare Revisits Power-Wheelchair Codes; ECRI Wants More iBOT Studies
ECRI recommends larger, longer-term studies of Johnson & Johnson/Independence Technology's iBOT 3000 stair-climbing power wheelchair to better determine the device's cost-to-benefit ratio
Medicare Revisits Power-Wheelchair Codes; ECRI Wants More iBOT Studies
ECRI recommends larger, longer-term studies of Johnson & Johnson/Independence Technology's iBOT 3000 stair-climbing power wheelchair to better determine the device's cost-to-benefit ratio
J&J iBOT 3000
National coverage determination will be sought for the stair-climbing wheelchair to enable payments beyond those provided by existing Medicare codes for power wheelchairs, according to the firm. The $29,000 device received PMA approval Aug. 13 (1"The Gray Sheet" Aug. 18, 2003, p. 3)...